# New Generation mRNA Booster Vaccine Against Emerging VOCs

> **NCT05580159** · PHASE3 · UNKNOWN · sponsor: **Stemirna Therapeutics** · enrollment: 2000 (estimated)

## Conditions studied

- Immunogenicity
- Efficacy
- Safety

## Interventions

- **BIOLOGICAL:** SW-BIC-213
- **BIOLOGICAL:** SARS-Cov-2 Vaccina(Vero Cell ) Inactivated

## Key facts

- **NCT ID:** NCT05580159
- **Lead sponsor:** Stemirna Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10
- **Primary completion:** 2023-05-11
- **Final completion:** 2023-05-11
- **Target enrollment:** 2000 (ESTIMATED)
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05580159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05580159, "New Generation mRNA Booster Vaccine Against Emerging VOCs". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05580159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*